EUVIMEDEUVIMED entdecken
Vergleichsstudie

Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study

Yunqi Hua, Yuqian Gao, Shuang Luo, Ge Song, Xiaoling Tian, Chenlin Wang, Shuang Lv, Xinyi Zhang, Guo Shao

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114487 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yunqi Hua und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Baotou Cancer Hospital, Baotou, Inner Mongolia 014040, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Programmed Cell Death 1 Receptor, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Previous trials have revealed better treatment efficacy of programmed cell death 1 (PD-1) inhibitors combined with chemotherapy as first-line treatments than chemotherapy alone in advanced gastric cancer (GC) patients, but real-world evidence is still lacking. Hence, this real-world study aimed to investigate the efficacy and safety of PD-1 inhibitors plus chemotherapy as first-line treatments compared with chemotherapy alone in advanced GC patients. METHODS: In total, 102 advanced GC patients were allocated into a combination group (receiving chemotherapy combined with a PD-1 inhibitor as a first-line treatment) (n = 48) or a chemotherapy group (receiving chemotherapy only as a first-line treatment) (n = 54) according to their actual treatment regimens. RESULTS: The objective response rate (ORR) was greater in the combination group than in the chemotherapy group (25.0 % versus 9.3 %, P = 0.033), whereas the disease control rate (DCR) was not different between the groups (83.3 % versus 66.7 %, P = 0.054). Progression-free survival (PFS) was prolonged in the combination group than in the chemotherapy group (P = 0.018). The median (95 % confidence interval) PFS was 19.7 (12.2-27.2) months in the combination group and 16.5 (7.3-25.7) months in the chemotherapy group. Multivariate logistic regression analyses revealed that PD-1 inhibitors combined with chemotherapy were independently associated with an increased ORR (odds ratio: 4.180, P = 0.024), increased DCR (odds ratio: 2.928, P = 0.049), and prolonged PFS (hazard ratio: 0.388, P = 0.030). No difference was found in total or each specific grade III-IV adverse reaction between the groups (all P > 0.05). CONCLUSION: Treatment with a PD-1 inhibitor plus chemotherapy as a first-line treatment shows better treatment efficacy with similar safety to that of chemotherapy alone in advanced GC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsProgrammed Cell Death 1 ReceptorAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeRetrospective StudiesProgression-Free Survival

Stichwörter der Autor:innen

Advanced gastric cancerChemotherapyProgrammed cell death 1 inhibitorSafety profilesTreatment efficacy

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Baotou Cancer Hospital, Baotou, Inner Mongolia 014040, China.
  • Department of Graduate School, Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014030, China.
  • Center for Translational Medicine, the Third People's Hospital of Longgang District & Longgang Institute of Medical Imaging, Shantou University Medical College, Shenzhen 518100, China. Electronic address: goushao0300549…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hua, Y., Gao, Y., Luo, S., Song, G., Tian, X., Wang, C., Lv, S., Zhang, X., & Shao, G. (2025). Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114487

Vancouver

Hua Y, Gao Y, Luo S, Song G, Tian X, Wang C, et al. Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114487

BibTeX
@article{Hua2025,
  author = {Hua, Yunqi and Gao, Yuqian and Luo, Shuang and Song, Ge and Tian, Xiaoling and Wang, Chenlin and Lv, Shuang and Zhang, Xinyi and Shao, Guo},
  title = {Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114487}
}
Kostenlos starten →